← Back to Home

Cell Therapy Expands to More Diseases: Legend Biotech Updates Cancer and Autoimmune Trial Progress

From newly diagnosed myeloma to solid tumors and autoimmune diseases, Legend Biotech’s pipeline reflects different paths for cell therapy. Some studies have moved into patient follow-up, but this update does not yet disclose complete data sufficient to assess efficacy.

By SURL BioNews

The next step for cell therapy involves more than which diseases it can treat: it also concerns when to intervene, how therapies are manufactured, and how long treatment effects can last. Legend Biotech updated its clinical pipeline on September 14, 2026, outlining three parallel research paths: moving myeloma treatment into newly diagnosed patients, expanding applications in solid tumors, and exploring allogeneic and in vivo cell therapies. The information provides an update on development progress, but it is not yet a complete report on efficacy.

In multiple myeloma, CARVYKTI, an autologous cell therapy targeting BCMA, is being evaluated for first-line treatment. CARTITUDE-5, for newly diagnosed patients not planning to undergo transplantation, and CARTITUDE-6, for transplant-eligible patients, are both listed as undergoing patient follow-up; CARTITUDE-10, which also studies newly diagnosed patients not planning to undergo transplantation, continues to enroll patients. These studies seek to determine whether using cell therapy earlier in the disease course can deliver benefits sufficient to support a change in treatment sequencing.

For solid tumors, the company marked two autologous cell therapy studies as having “achieved the primary endpoint, with patient follow-up ongoing”: LB1908 targets Claudin 18.2 for relapsed or refractory gastric and pancreatic cancers; LB2102 targets DLL3 for small cell lung cancer and large cell neuroendocrine carcinoma in the second-line setting or later. However, the pipeline chart did not specify how the primary endpoints were defined or provide response rates, survival outcomes, or adverse events. This designation alone therefore cannot establish that the two therapies have demonstrated anticancer efficacy.

Another path shifts the focus to relapsed or refractory autoimmune diseases. LB2404D, which is enrolling patients, is an allogeneic CAR-γδ T-cell therapy candidate targeting both CD19 and CD70; LB2405 uses allogeneic CAR-NK cells targeting CD19 and BCMA. Compared with autologous therapies manufactured from patients’ own cells, allogeneic therapies use cells from other sources, so their development involves different manufacturing and immune compatibility issues. This update did not specify individual diseases or report patient outcomes from these two studies.

The company also listed progress in in vivo cell therapies. LB2501, which targets CD19 and CD20 and is being studied in relapsed or refractory B-cell non-Hodgkin lymphoma, and LB2503, which targets GPRC5D and is being studied in relapsed or refractory multiple myeloma, are both enrolling patients; LB2505, which also addresses myeloma and targets BCMA, is in the start-up phase. This path aims to move cell modification into the patient’s body, but the pipeline chart did not disclose delivery methods or results demonstrating the approach in humans, so its practical advantages cannot yet be assessed.

The allogeneic autoimmune disease and in vivo therapy programs described above are all identified as Phase 1 investigator-initiated trials conducted in China. There is still a gap between this stage of research and large confirmatory trials; “enrolling” indicates that a study is progressing, not that efficacy has been confirmed. The company also explicitly stated that the safety and efficacy of the investigational drugs and uses have not been established, and that eventual approval or commercialization cannot be guaranteed.

This pipeline update outlines plans to extend cell therapy across different diseases and manufacturing approaches. Determining which of these directions can truly improve patient care will still require trial designs, participant numbers, duration of effect, and safety data. Particularly for studies that have moved into follow-up, long-term results will reveal more about a treatment’s value than a single progress label.

References

  1. Stock Titan
  2. Legend Biotech / SEC EDGAR